biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
23:40 New kind of prostate cancer drug showed promising signs, Yale team reports✦23:36 Cell therapy erased signs of hard-to-treat lymphoma in 3 of 4, maker says✦23:36 Gene fix for sickle cell freed 3 patients from transfusions, maker says✦17:43 Salt swap could prevent nearly 3 million deaths a year, model estimates✦17:40 Regrowth from a shot for patchy hair loss held after stopping, maker says✦11:41 Broccoli compound helped lab cells break down a hair-loss hormone✦11:40 NHS trial offers a blood test for 13 cancers to 20,000 people with symptoms✦11:37 Anti-aging supplement improved blood vessel measures in a 61-person trial✦23:40 New kind of prostate cancer drug showed promising signs, Yale team reports✦23:36 Cell therapy erased signs of hard-to-treat lymphoma in 3 of 4, maker says✦23:36 Gene fix for sickle cell freed 3 patients from transfusions, maker says✦17:43 Salt swap could prevent nearly 3 million deaths a year, model estimates✦17:40 Regrowth from a shot for patchy hair loss held after stopping, maker says✦11:41 Broccoli compound helped lab cells break down a hair-loss hormone✦11:40 NHS trial offers a blood test for 13 cancers to 20,000 people with symptoms✦11:37 Anti-aging supplement improved blood vessel measures in a 61-person trial
← All story threadsSTORY THREAD

Lyell's two-target cell therapy for lymphoma.

1 report so far. New developments are added to this thread as they happen.

  1. Nov 4, 2026
    KEY TRIAL DATA: 91% RESPOND, 77% SHOW NO CANCERCompany results · 81 people

    Cell therapy erased signs of hard-to-treat lymphoma in 3 of 4, maker says

    Lyell says its souped-up immune-cell therapy left no detectable cancer in 77% of 44 people whose lymphoma had come back. Full results are due at a December meeting.